Cited 0 time in
Primary Intramedullary Spinal Sarcoma : A Case Report and Review of the Current Literatures
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Su-Hyeong | - |
| dc.contributor.author | Bak, Koang-Hum | - |
| dc.contributor.author | Kim, Dong Won | - |
| dc.contributor.author | Kang, Tae-Hoon | - |
| dc.date.accessioned | 2022-12-20T11:07:44Z | - |
| dc.date.available | 2022-12-20T11:07:44Z | - |
| dc.date.issued | 2010-11 | - |
| dc.identifier.issn | 2005-3711 | - |
| dc.identifier.issn | 1598-7876 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/173500 | - |
| dc.description.abstract | Primary central nervous system (CNS) sarcomas are exceedingly rare, and, to the best of our knowledge, there has not yet been a report of intramedullary sarcoma. Here, we report a primary intradural intramedullary sarcoma of the spinal cord in a four-year-old boy who presented with low back pain and a radiculopathy involving both lower extremities. The tumor showed significant enhancement on magnetic resonance (MR) images due to its extreme vascularity. Gross total tumor removal was performed with microelectrical pulse recording, and the patient also received adjuvant radiotherapy and chemotherapy. After the operation, the patient's sensory deficits were improved. Because CNS dissemination is common, entire neuraxis evaluation is essential, although there was no evidence of dissemination in this case. The prognosis of primary CNS sarcoma is poor due to infiltrative nature and early CNS dissemination is common, and the treatment of choice is radical surgical resection. Adjuvant therapy is also beneficial with radiotherapy and chemotherapy. | - |
| dc.format.extent | 4 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한신경외과학회 | - |
| dc.title | Primary Intramedullary Spinal Sarcoma : A Case Report and Review of the Current Literatures | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3340/jkns.2010.48.5.448 | - |
| dc.identifier.scopusid | 2-s2.0-79751499826 | - |
| dc.identifier.wosid | 000286482000012 | - |
| dc.identifier.bibliographicCitation | Journal of Korean Neurosurgical Society, v.48, no.5, pp 448 - 451 | - |
| dc.citation.title | Journal of Korean Neurosurgical Society | - |
| dc.citation.volume | 48 | - |
| dc.citation.number | 5 | - |
| dc.citation.startPage | 448 | - |
| dc.citation.endPage | 451 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Neurosciences & Neurology | - |
| dc.relation.journalResearchArea | Surgery | - |
| dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
| dc.relation.journalWebOfScienceCategory | Surgery | - |
| dc.subject.keywordPlus | MALIGNANT FIBROUS HISTIOCYTOMA | - |
| dc.subject.keywordPlus | CENTRAL-NERVOUS-SYSTEM | - |
| dc.subject.keywordPlus | PRIMARY INTRACRANIAL SARCOMAS | - |
| dc.subject.keywordPlus | PRIMARY RHABDOMYOSARCOMA | - |
| dc.subject.keywordPlus | FEATURES | - |
| dc.subject.keywordPlus | CORD | - |
| dc.subject.keywordPlus | NEOPLASMS | - |
| dc.subject.keywordPlus | CHILDREN | - |
| dc.subject.keywordPlus | GLIOMA | - |
| dc.subject.keywordPlus | TUMORS | - |
| dc.subject.keywordAuthor | Central nervous system | - |
| dc.subject.keywordAuthor | Intramedullary | - |
| dc.subject.keywordAuthor | Primary | - |
| dc.subject.keywordAuthor | Sarcoma | - |
| dc.identifier.url | https://www.jkns.or.kr/journal/view.php?doi=10.3340/jkns.2010.48.5.448 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
